Form 10-Q DANAHER CORP /DE/ For: Mar 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Danaher (DHR) PT Lowered to $260 at JPMorgan
April 22, 2025 1:45 PM EDTJPMorgan analyst Tycho W. Peterson lowered the price target on Danaher (NYSE: DHR) to $260.00 (from $280.00) while maintaining a Overweight rating.
The analyst comments "Like we noted in our first take earlier this morning, 1Q25 results (PR/Presentation/non-GAAP recs/Earnings supplement/10-Q) came in above expectations with notable performance in bioprocessing, while 2025 topline guidance was reiterated and bottom line guidance initiated bracketing the Street. 1Q non-GAAP core revenue growth was flat (vs. Street of -2.3% and guide of -LSD) as bioprocessing revenue grew +HSD in 1Q (consumables +LDD) with... More
